4IPF

The 1.7A crystal structure of humanized Xenopus MDM2 with RO5045337


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.7 Å
  • R-Value Free: 0.229 
  • R-Value Work: 0.208 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history

Literature

MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models.

Tovar, C.Graves, B.Packman, K.Filipovic, Z.Xia, B.H.Tardell, C.Garrido, R.Lee, E.Kolinsky, K.To, K.H.Linn, M.Podlaski, F.Wovkulich, P.Vu, B.Vassilev, L.T.

(2013) Cancer Res. 73: 2587-2597

  • DOI: 10.1158/0008-5472.CAN-12-2807
  • Also Cited By: 4J3E, 4JRG, 4JSC

  • PubMed Abstract: 
  • MDM2 negatively regulates p53 stability and many human tumors overproduce MDM2 as a mechanism to restrict p53 function. Thus, inhibitors of p53-MDM2 binding that can reactivate p53 in cancer cells may offer an effective approach for cancer therapy. R ...

    MDM2 negatively regulates p53 stability and many human tumors overproduce MDM2 as a mechanism to restrict p53 function. Thus, inhibitors of p53-MDM2 binding that can reactivate p53 in cancer cells may offer an effective approach for cancer therapy. RG7112 is a potent and selective member of the nutlin family of MDM2 antagonists currently in phase I clinical studies. RG7112 binds MDM2 with high affinity (K(D) ~ 11 nmol/L), blocking its interactions with p53 in vitro. A crystal structure of the RG7112-MDM2 complex revealed that the small molecule binds in the p53 pocket of MDM2, mimicking the interactions of critical p53 amino acid residues. Treatment of cancer cells expressing wild-type p53 with RG7112 activated the p53 pathway, leading to cell-cycle arrest and apoptosis. RG7112 showed potent antitumor activity against a panel of solid tumor cell lines. However, its apoptotic activity varied widely with the best response observed in osteosarcoma cells with MDM2 gene amplification. Interestingly, inhibition of caspase activity did not change the kinetics of p53-induced cell death. Oral administration of RG7112 to human xenograft-bearing mice at nontoxic concentrations caused dose-dependent changes in proliferation/apoptosis biomarkers as well as tumor inhibition and regression. Notably, RG7112 was highly synergistic with androgen deprivation in LNCaP xenograft tumors. Our findings offer a preclinical proof-of-concept that RG7112 is effective in treatment of solid tumors expressing wild-type p53.


    Related Citations: 
    • In Vivo Activation of the P53 Pathway by Small-Molecule Antagonists of Mdm2
      Vassilev, L.T.,Vu, B.T.,Graves, B.,Carvajal, D.,Podlaski, F.,Filipovic, Z.,Kong, N.,Kammlott, U.,Lukacs, C.,Klein, C.,Fotouhi, N.,Liu, E.A.
      (2004) Science 303: 844


    Organizational Affiliation

    Roche Research Center, Hoffmann-La Roche Inc., Nutley, NJ 07110, USA.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
E3 ubiquitin-protein ligase Mdm2
A
85Xenopus laevisGene Names: mdm2
EC: 6.3.2.-
Find proteins for P56273 (Xenopus laevis)
Go to UniProtKB:  P56273
Small Molecules
Ligands 2 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
SO4
Query on SO4

Download SDF File 
Download CCD File 
A
SULFATE ION
O4 S
QAOWNCQODCNURD-UHFFFAOYSA-L
 Ligand Interaction
1F0
Query on 1F0

Download SDF File 
Download CCD File 
A
[(4S,5R)-2-(4-tert-butyl-2-ethoxyphenyl)-4,5-bis(4-chlorophenyl)-4,5-dimethyl-4,5-dihydro-1H-imidazol-1-yl]{4-[3-(methylsulfonyl)propyl]piperazin-1-yl}methanone
RO5045337, RG7112
C38 H48 Cl2 N4 O4 S
QBGKPEROWUKSBK-QPPIDDCLSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
1F0IC50: 18 nM BINDINGMOAD
1F0IC50: 18 nM PDBBIND
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.7 Å
  • R-Value Free: 0.229 
  • R-Value Work: 0.208 
  • Space Group: C 2 2 21
Unit Cell:
Length (Å)Angle (°)
a = 43.083α = 90.00
b = 67.493β = 90.00
c = 66.724γ = 90.00
Software Package:
Software NamePurpose
CNXrefinement
d*TREKdata reduction
d*TREKdata scaling
CrystalCleardata collection
MOLREPphasing

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2013-02-20
    Type: Initial release
  • Version 1.1: 2013-04-24
    Type: Database references